Cancer drug model could be a potential treatment for Alzheimer’s, study claims

Treatments modelled on the cancer drug Gleevec could potentially prevent the formation of amyloid plaques - one of the major hallmarks of Alzheimer's disease according to a study published in the journal Nature today (Wednesday 1 September).

Researchers at the Laboratory of Molecular and Cellular Neuroscience in the U.S. tested the drug on mice and found that Gleevec has the ability to attach itself to a protein (GSAP). GSAP promotes the production of plaques in the brain and is therefore a potential target for anti-amyloid treatments.

Alzheimer's Society comment:

'This study provides us with exciting new information about a protein that has been found to promote the production of amyloid plaques - a major hallmark of Alzheimer's disease. Although the drug highlighted in the report targets this protein and is available and safety tested, this research is in the early stages and we are some way from this being a viable treatment for Alzheimer's.

'A million people will develop dementia in the next ten years yet dementia research receives eight times less investment than cancer research. We must invest now if we are to move forward in the development of effective Alzheimer's treatments.'

Dr Susanne Sorensen
Head of Research
Alzheimer's Society

- Ends -

Ref: Gen He et al., 'Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease', Nature, 2 September 2010

Notes to editors:

• One in three people over 65 will die with dementia
• Alzheimer's Society research shows that 750,000 people in the UK have a form of dementia, more than half have Alzheimer's disease. In just 15 years a million people will be living with dementia. This will soar to 1.7 million people by 2051.
• Alzheimer's Society champions the rights of people living with dementia and the millions of people who care for them. 
• Alzheimer's Society works in England, Wales and Northern Ireland
• Alzheimer's Society supports people to live well with dementia today and funds research to find a cure for tomorrow. We rely on voluntary donations to continue our vital work. You can donate now by calling 0845 306 0898 or visiting alzheimers.org.uk 
• Alzheimer's Society provides a National Dementia Helpline, the number is 0845 300 0336 or visit alzheimers.org.uk

Press Office 0207 423 3595 Email: press@alzheimers.org.uk